Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12680309 | 0.73 | MAPK1 (0.42) | MAPK1ALDH1A1HTTVDRSMN1; SMN2 | |
| SCHEMBL11749841 | 0.73 | MAPK1 (0.42) | MAPK1ALDH1A1HTTVDRSMN1; SMN2 | |
| SCHEMBL18470997 | 0.72 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL3363554 | 0.71 | CYP2D6 (0.36) | TDP1 | |
| SCHEMBL5496757 | 0.70 | — | — | |
| SCHEMBL4187798 | 0.70 | — | — | |
| SCHEMBL19295797 | 0.69 | — | — | |
| SCHEMBL5541116 | 0.69 | MAPK1 (0.39) | MAPK1ALDH1A1HTTVDRSMN1; SMN2 | |
| SCHEMBL18751670 | 0.69 | CES2 (0.43) | MAPK1ALDH1A1HTTVDRSMN1; SMN2 | |
| SCHEMBL5496754 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| US-6645971-B1 | Pollakiuria and urinary incontinence treatment; muscarinic receptor antagonists; anticholinergic, anticonvulsants, antiulcer, and antiasthmatics; Parkinson*s disease | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-11-11 | — | — | US | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
| EP-1122253-A1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-0022245-A2 | Aminothiadiazolyl derivatives, process for their preparation, pharmaceutical compositions containing them;starting compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | MAPK1 1878/4885ALDH1A1 2899/4885HTT 4561/4885 |
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | MAPK1 1413/4885ALDH1A1 2901/4885HTT 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.